Global Cord Blood
CORBF
$1.25
Share price
0.00%
Change (1 day)
-58.19%
Change (1 year)
Categories
Revenue for Global Cord Blood (CORBF)
Revenue in 2022 (TTM): $0.19 B
According to Global Cord Blood's latest financial reports the company's current revenue (TTM) is $0.19 B. In 2021 the company made a revenue of $0.19 B an increase over the years 2020 revenue that were of $0.16 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Global Cord Blood from 2009 to 2022
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2022 (TTM) | $0.19 B | 0.43% |
| 2021 | $0.19 B | 14.62% |
| 2020 | $0.16 B | -0.49% |
| 2019 | $0.16 B | 16.46% |
| 2018 | $0.14 B | 7.44% |
| 2017 | $0.13 B | 26.49% |
| 2016 | $0.10 B | 0.78% |
| 2015 | $0.10 B | 5.17% |
| 2014 | $0.10 B | 11.51% |
| 2013 | $90.46 M | 15.41% |
| 2012 | $78.38 M | 34.03% |
| 2011 | $58.48 M | 24.33% |
| 2010 | $47.03 M | 68.27% |
| 2009 | $27.95 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 RadNet RDNT | $1.61 B | 733.91% | 🇺🇸 USA |
 National Healthcare
NHC | $1.14 B | 488.85% | 🇺🇸 USA |
 NeoGenomics
NEO | $0.59 B | 205.19% | 🇺🇸 USA |
 Cryo-Cell CCEL | $31.34 M | -83.83% | 🇺🇸 USA |